SELLAS Life Sciences Group, Inc. Cost of Revenue
SELLAS Life Sciences Group, Inc. (SLS) reported Cost of Revenue of $468.00 thousand for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-06.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2015-08-06
- SELLAS Life Sciences Group, Inc. cost of revenue for the quarter ending 2015-06-30 was $468.00K, a 34.87% increase year-over-year.
- SELLAS Life Sciences Group, Inc. cost of revenue for the quarter ending 2015-03-31 was $393.00K, a 18.73% increase year-over-year.
- SELLAS Life Sciences Group, Inc. cost of revenue for the quarter ending 2014-12-31 was $478.00K, a 82.44% increase year-over-year.
- SELLAS Life Sciences Group, Inc. cost of revenue for the quarter ending 2014-09-30 was $247.00K, a 4.26% decline year-over-year.
- SELLAS Life Sciences Group, Inc. cost of revenue for fiscal 2014 was $1.40M, a 169.81% increase from fiscal 2013.
- SELLAS Life Sciences Group, Inc. cost of revenue for fiscal 2013 was $520.00K.
- SELLAS Life Sciences Group, Inc. cost of revenue for fiscal 2012 was $0.00.
- SELLAS Life Sciences Group, Inc. cost of revenue for fiscal 2011 was $0.00.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month |
|---|---|---|---|---|---|---|
| 2015-06-30 | $468.00K 10-Q · filed 2015-08-06 | $861.00K 10-Q · filed 2015-08-06 | $1.34M derived: sum of 3 quarters · filed 2015-08-06 | $1.59M derived: sum of 4 quarters · filed 2015-08-06 | ||
| 2015-03-31 | $393.00K 10-Q · filed 2015-05-07 | $871.00K derived: sum of 2 quarters · filed 2015-05-07 | $1.12M derived: sum of 3 quarters · filed 2015-05-07 | $1.47M derived: sum of 4 quarters · filed 2015-08-06 | ||
| 2014-12-31 | $478.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-05 | $725.00K derived: sum of 2 quarters · filed 2015-03-05 | $1.07M derived: sum of 3 quarters · filed 2015-08-06 | $1.40M 10-K · filed 2015-03-05 | ||
| 2014-09-30 | $247.00K 10-Q · filed 2014-11-05 | $594.00K derived: sum of 2 quarters · filed 2015-08-06 | $925.00K 10-Q · filed 2014-11-05 | $1.19M derived: sum of 4 quarters · filed 2015-08-06 | ||
| 2014-06-30 | $347.00K 10-Q · filed 2015-08-06 | $678.00K 10-Q · filed 2015-08-06 | $940.00K derived: sum of 3 quarters · filed 2015-08-06 | $1.20M derived: sum of 4 quarters · filed 2015-08-06 | ||
| 2014-03-31 | $331.00K 10-Q · filed 2015-05-07 | $593.00K derived: sum of 2 quarters · filed 2015-05-07 | $851.00K derived: sum of 3 quarters · filed 2015-05-07 | $851.00K derived: sum of 4 quarters · filed 2015-05-07 | ||
| 2013-12-31 | $262.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-05 | $520.00K derived: sum of 2 quarters · filed 2015-03-05 | $520.00K derived: sum of 3 quarters · filed 2015-03-05 | $520.00K 10-K · filed 2015-03-05 | ||
| 2013-09-30 | $258.00K 10-Q · filed 2014-11-05 | $301.00K 10-Q · filed 2013-11-06 | $258.00K derived: sum of 2 quarters · filed 2014-11-05 | $258.00K 10-Q · filed 2014-11-05 | $301.00K 10-Q · filed 2013-11-06 | $258.00K derived: sum of 4 quarters · filed 2015-03-05 |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-11 | $0.00 10-Q · filed 2014-08-11 | $0.00 derived: sum of 3 quarters · filed 2015-03-05 | $0.00 derived: sum of 4 quarters · filed 2015-03-05 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-06 | $0.00 derived: sum of 2 quarters · filed 2015-03-05 | $0.00 derived: sum of 3 quarters · filed 2015-03-05 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-03-05 | $0.00 derived: sum of 2 quarters · filed 2015-03-05 | $0.00 10-K · filed 2015-03-05 | |||
| 2012-09-30 | $0.00 10-Q/A · filed 2013-11-07 | $0.00 10-Q/A · filed 2013-11-07 | ||||
| 2011-12-31 | $0.00 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |